Académique Documents
Professionnel Documents
Culture Documents
Today will offer news for investors in William Demant and GN Great Nordic as the Italian hearing-aid
dealer Amplifon will release its interim accounts. These accounts will attract additional attention as
the French company Audika reported quite a negative surprise when it revealed lower-than-expected
sales figures for Q2.
Moreover, investors in D/S Norden will see a couple of indicators for the development in the dry-bulk
market when the rivals Diana Shipping and DryShips announce their Q2 accounts today.
It is expected that today the Danish market will open – as it closed yesterday – in positive territory as
the DAX future has increased by 0.55%.
Sanofi-Aventis (BUY):
Expectations of the quarterly accounts. JB: It has been and will still be an eventful week for SA in respect
of the FDA approval of a generic rival of Lovenox last Friday and the Q2 accounts to be released on
Thursday, 29 July. For Q2, we expect results with sales 2.5% above the level for Q2 2009, while the
profit will be worse than last year. Moreover, the impact of the US health-care reform and the European
price pressure on SA’s profit will attract attention. We maintain our BUY recommendation for SA but
lower the price target to 64 (from 67) due to the lower expected sales and margin for Lovenox.
2
EQUITIES DAILY
Equity Research • 28 July 2010
Lufthansa (BUY):
We maintain our BUY recommendation. JB: Even though the volcanic ash cloud resulted in high
expenses, we expect that due to the traffic figures released lately, Lufthansa will report decent Q2
accounts, considerably above Q1 2010 and the basis of comparison, Q2 2009. We reiterate our BUY
recommendation for Lufthansa and our price target at EUR 15, as we think the worst part is over, and
that in the coming years Lufthansa will see gradually improving market conditions.
Samsung (SELL):
Samsung will release its Q2 2010 accounts early Friday morning. JB: Already in July, Samsung
announced the main figures, and therefore the accounts are not awaited with that much excitement.
Samsung reported sales of KRW 37 trillion and operating earnings of KRW 5 trillion, i.e. in the middle
of Samsung’s forecast range. Growth is primarily fuelled by DRAM/NAND but also sales of TFT-LCD
screens are good. We reiterate our SELL recommendation for Samsung, as we think the consensus
estimates are too high and do not reflect the high risk of excess capacity in respect of LCD and memory
chips. We have previously seen excess capacity on several occasions and such a situation will result in
drastically declining market prices.
3
EQUITIES DAILY
Equity Research • 28 July 2010
340 10.100
10.000
335
9.900
330
9.800
325
9.700
320
9.600
315 9.500
5400 70
68
5300
66
5200
64
5100 62
Switch recommendation
Jyske Bank recommends the following switches:
From Genmab (REDUCE) to NeuroSearch (BUY).
From D/S Norden (REDUCE) and Torm (REDUCE) to A.P. Møller-Mærsk (ACCUMULATE)
From William Demant (REDUCE) and GN Great Nordic (REDUCE) to Coloplast (ACCUMULATE)
From Pfizer (SELL) to Sanofi-Aventis (BUY)
From Novo Nordisk (REDUCE) to Sanofi-Aventis (BUY) and Novozymes (BUY)
From FLSmidth (REDUCE) to NKT Holding (BUY)
From Nordea (REDUCE) to Danske Bank (BUY)
4
EQUITIES DAILY
Equity Research • 28 July 2010
Macroeconomic events
Time Event
US
14:30 USD New orders, durable consumer goods
- exclusive of transport
20:00 USD The Fed publishes Beige Book
European
N/A DEM Consumer prices, preliminary
Asian and others
NZD Monetary policy meeting at the Reserve Bank of New Zealand
23:00 NZD Interest-rate announcement from the Reserve Bank of New Zealand
00:45 NZD Trade balance
01:50 NZD Retail sales
Yours faithfully,
JYSKE MARKETS
Jyske Bank
Equities
5
EQUITIES DAILY
Equity Research • 28 July 2010
Jyske Bank's analysts are subject to the recommendations of The Danish Securities Dealers Association on the handling of conflicts of interest in investment
banks.
The research report is based on information which Jyske Bank finds reliable, but Jyske Bank does not assume any responsibility for the correctness of the material
nor for transactions made on the basis of the information or the estimates of the report. The estimates and recommendations of the research report may be
changed without notice. The report is for the personal use of Jyske Bank's customers and may not be copied.
Conflicss of interest
Jyske Bank has prepared procedures to prevent and preclude conflicts of interest thus ensuring that research reports are being prepared in an objective manner.
These procedures have been incorporated in the business procedures covering the research activities of Jyske Markets, a business unit of Jyske Bank.
Moreover, equity analysts at Jyske Bank cannot trade in companies and papers for which they prepare research reports. Jyske Bank may, however, hold positions,
have interests in or business relations with the companies that are analysed. The research report has not been presented to the company prior to its release. The
analysts receive no payment from persons interested in individual research reports.
Allocation of recommendations, Danish shares (number) Allocation of recommendations, all shares (number)
14
20
12
10 15
8
10
6
4 5
2
0 0
Buy Accumulate Neutral Reduce Sell Buy Accumulate Neutral Reduce Sell
Risk
Investment in this share is associated with a risk. Movements in the equity market, the sector and/or news flows, etc. regarding the company may affect the
price of the share. See the front page of the research report for our view of the risk associated with the share. The risk factors stated and/or calculations of
sensitivities in the research report are not to be considered all-encompassing. If the share is traded in a currency other than the investor’s base currency, the
investor accepts an FX risk. In connection with an ADR or similar papers, the FX risk exists relative to the currency in which the underlying share trades.
6
EQUITIES DAILY
Equity Research • 28 July 2010
Recommendation Return relative to the performance of the
general equity market
BUY >5%
ACCUMULATE 0 to 5%
NEUTRAL 0%
REDUCE 0 to -5%
SELL < -5%
Source: Jyske Bank
Since our recommendations are relative and risk-adjusted, it is possible to compare our recommendations across sectors and risk categories. In addition, the
potential is stated in absolute terms via our price target. It should be borne in mind, however, that the recommendation is the anchor. A BUY recommendation is
a BUY recommendation until the recommendation has been changed, also in the event that price increases have taken the price "too close" to the price target.
The future and historical returns estimated in the research report are stated as returns before costs since returns after costs depend on a number of factors
relating to individual customer relations, custodian charges, volume of trade as well as market-, currency- and product-specific factors. It is not certain that the
share will yield the stated expected future return/s. The stated expected future returns exclusively express our best assessment.